2023-01-18
Phase Ib/IIa clinical study of ImmuneOnco IMM01 combined with bortezomib and dexamethasone in the treatment of multiple myeloma has been approved by the National Medical Products Administration (NMPA)
On January 18, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the Phase Ib/IIa clinical study of the first domestic SIRPαFc fusion protein
View more
